Myeloma CNS Business Case

This document has been designed to support the development of a business case for the role of a myeloma Clinical Nurse Specialist (CNS). It should be used in conjunction with local Trust practice.



AWMSG recommendations on the use of plerixafor

AWMSG has recommended the use of plerixafor (MozobilĀ®) as an option within NHS Wales in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells in myeloma patients whose cells mobilise poorly. Patients may use plerixafor if they have already failed one complete mobilisation attempt.


SMC advice on the use of bortezomib subcutaneous injection

SMC advice on the use of subcutaneous bortezomib injection within NHS Scotland in combination with melphalan and prednisone for the treatment of previously untreated non-transplant eligible myeloma patient or for the treatment of relapsed myeloma patients who have received at least one prior treatment and who have already undergone or are not transplant eligible.